Production (Stage)
X4 Pharmaceuticals, Inc.
XFOR
$3.10
-$0.13-4.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 31.36M | 2.56M | 1.12M | 563.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.36M | 2.56M | 1.12M | 563.00K | -- |
| Cost of Revenue | 5.51M | 797.00K | 495.00K | 268.00K | -- |
| Gross Profit | 25.85M | 1.76M | 628.00K | 295.00K | -- |
| SG&A Expenses | 59.10M | 61.52M | 56.30M | 48.77M | 45.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 144.92M | 143.96M | 132.01M | 124.16M | 115.51M |
| Operating Income | -113.56M | -141.40M | -130.89M | -123.60M | -115.51M |
| Income Before Tax | 14.92M | -37.14M | -16.67M | 17.73M | -128.82M |
| Income Tax Expenses | 325.00K | 310.00K | 85.00K | 96.00K | 93.00K |
| Earnings from Continuing Operations | 14.60 | -37.45 | -16.76 | 17.63 | -128.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.60M | -37.45M | -16.76M | 17.63M | -128.91M |
| EBIT | -113.56M | -141.40M | -130.89M | -123.60M | -115.51M |
| EBITDA | -112.35M | -140.61M | -130.30M | -123.18M | -115.15M |
| EPS Basic | 2.27 | -5.54 | -2.54 | 2.59 | -20.91 |
| Normalized Basic EPS | -8.37 | -13.25 | -11.40 | -8.19 | -13.06 |
| EPS Diluted | 2.17 | -5.64 | -2.65 | 2.48 | -20.93 |
| Normalized Diluted EPS | -8.37 | -13.25 | -11.40 | -8.19 | -13.06 |
| Average Basic Shares Outstanding | 26.98M | 26.81M | 26.67M | 26.54M | 25.48M |
| Average Diluted Shares Outstanding | 27.02M | 26.82M | 26.68M | 26.55M | 25.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |